In8bio Inc Stock Today
| INAB Stock | USD 0.26 0.01 3.70% |
PerformanceVery Weak
| Odds Of DistressVery High
|
In8bio is trading at 0.26 as of the 26th of February 2025, a 3.7 percent decrease since the beginning of the trading day. The stock's open price was 0.27. In8bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of July 2021 | Category Healthcare | Classification Health Care |
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. The company has 72.48 M outstanding shares of which 433.21 K shares are currently shorted by private and institutional investors with about 0.56 trading days to cover. More on In8bio Inc
Moving against In8bio Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
In8bio Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIn8bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand In8bio's financial leverage. It provides some insight into what part of In8bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
In8bio Inc (INAB) is traded on NASDAQ Exchange in USA. It is located in 350 5th Avenue, New York, NY, United States, 10118 and employs 18 people. In8bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 18.49 M. In8bio Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 72.48 M outstanding shares of which 433.21 K shares are currently shorted by private and institutional investors with about 0.56 trading days to cover.
In8bio Inc currently holds about 25.74 M in cash with (23.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check In8bio Probability Of Bankruptcy
Ownership AllocationIn8bio Inc secures a total of 72.48 Million outstanding shares. 30% of In8bio Inc outstanding shares are owned by institutions. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Therefore, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check In8bio Ownership Details
In8bio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2024-12-31 | 59.6 K | |
| Ubs Group Ag | 2024-12-31 | 58.9 K | |
| Xtx Topco Ltd | 2024-12-31 | 42.4 K | |
| Overbrook Management Corp | 2024-12-31 | 33.8 K | |
| Virtu Financial Llc | 2024-12-31 | 22 K | |
| Tower Research Capital Llc | 2024-12-31 | 18.6 K | |
| Lpl Financial Corp | 2024-12-31 | 11.3 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 10.2 K | |
| Hightower Advisors, Llc | 2024-12-31 | 10 K | |
| Bios Capital Management, Lp | 2024-12-31 | 8.6 M | |
| Aigh Capital Management, Llc | 2024-12-31 | 6.2 M |
In8bio Historical Income Statement
In8bio Stock Against Markets
In8bio Corporate Management
| Pharm MPH | VP Communications | Profile | |
| TaiWei Ho | President, CoFounder | Profile | |
| William Ho | President, CoFounder | Profile | |
| Trishna MD | Chief Officer | Profile | |
| Kate Rochlin | Chief Officer | Profile | |
| Lawrence Lamb | CoFounder VP | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in In8bio Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In8bio. If investors know In8bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In8bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of In8bio Inc is measured differently than its book value, which is the value of In8bio that is recorded on the company's balance sheet. Investors also form their own opinion of In8bio's value that differs from its market value or its book value, called intrinsic value, which is In8bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In8bio's market value can be influenced by many factors that don't directly affect In8bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In8bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if In8bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In8bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.